Additionally, CEA levels in patients with colon cancer and type 2 diabetes mellitus, specifically those expressing SGLT2 but not UTG1A9, initially decreased after treatment with DAPA following radiotherapy, but subsequently increased upon discontinuation of DAPA. This evidence concerns the gene SLC5A2 and colonic neoplasm.